The Siemens Healthineers Atellica IM High-Sensitivity Troponin I (TnIH) test helps healthcare providers identify patients at risk of death and major cardiac events that could occur up to one year after presenting to the emergency department with signs and symptoms of acute coronary syndrome. The Atellica IM TnIH blood test measures cardiac troponin I in a patient’s blood, a specific and sensitive biomarker that indicates heart muscle injury. For the large number of chest pain patients who do not receive a heart attack diagnosis, the test may provide information about their impending risk. With a 10-minute time to first result, the Atellica IM TnIH test can be used as an aid in prognosis for 30-, 90-, 182-, and 365-day all-cause mortality and major adverse cardiac events in patients presenting with signs and symptoms suggestive of acute coronary syndrome.